moneyheap
IOVA · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Iovance Biotherapeutics, Inc. Common Stock (IOVA) stock moving?
IOVA fell sharply after its Oct 29 update on the IOV-LUN-202 lung cancer trial, closing at $9.56 from $14.81 (down about 35%) on roughly 59M shares, about six times normal volume. The updated data kept a 24.6% ORR in 69 non-squamous mNSCLC patients, close to the earlier 25.6%, but the company now highlights a retrospective KRAS wild-type, HER2 wild-type, smoker or former-smoker subgroup with a 59.1% ORR in 22 patients, which investors may view as a smaller, post-hoc group. Shares then slid to $7.74 on Nov 5, the day of Q3 results, even though revenue was a record ~$122M (up ~80% year over year), gross margin was ~60%, and EPS of $(0.05) beat the $(0.09) estimate. Full-year 2026 revenue guidance of $410-420M was affirmed against a $416.3M consensus. Analysts have since raised targets: UBS Neutral with an $8 target (Nov 3), Citizens Market Outperform with a $12 target (Nov 6), and Barclays Overweight with a $19 target (Nov 6). Pomerantz LLP announced an investigation into potential securities claims on Nov 6; this is an investor notice, not a filed lawsuit. The stock has recovered to $8.08 on Nov 10 but remains about 45% below the Oct 28 close, and volume has eased to about 10.1M. Upcoming catalysts include POSITILITY enrollment starting in November 2026, completion of enrollment in Cohorts 1 and 2, and a planned sBLA submission in 2027.
News behind the analysis
- Iovance Biotherapeutics Reports Record Third Quarter 2026 Revenue of ~$122M, Business Achievements, and Corporate UpdatesQ3 2026 total product revenue rose about 80% year over year to about $122M, with gross margin near 60% and U.S. Amtagvi revenue of about $102M.
- Iovance Biotherapeutics Q3 EPS $(0.05) Beats $(0.09) Estimate, Sales $121.469M Beat $115.982M EstimateThird-quarter EPS loss was smaller than expected and sales beat consensus by about $5.5M.
- Iovance Biotherapeutics Affirms FY2026 Sales Guidance of $410.000M-$420.000M vs $416.263M EstThe company reaffirmed full-year 2026 revenue guidance of $410M to $420M, which brackets the $416.3M consensus estimate.
- Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $19Barclays kept its Overweight rating and raised its price target to $19 after the quarter.
- Citizens Maintains Iovance Biotherapeutics at Market Outperform and Raises Price TargetCitizens kept its Market Outperform rating and raised its price target from $8 to $12.
- UBS Maintains Neutral Rating on Iovance Biotherapeutics and Raises Price Target to $8UBS kept a Neutral rating and raised its price target from $7 to $8.
- Investor Alert: Pomerantz Law Firm Investigates Claims on Behalf of InvestorsPomerantz LLP announced it is investigating Iovance for potential securities claims or unlawful business practices. This is an investigation notice, not a filed lawsuit.
- Iovance Reports Updated IOV-LUN-202 Results and Adds Precision TIL Strategy for Second-Line Metastatic Non-Small-Cell Lung Cancer (mNSCLC)Updated Phase 2 data in 69 non-squamous mNSCLC patients showed a 24.6% ORR, with a 59.1% ORR in a retrospective biomarker-enriched subgroup of 22 patients that the company plans to test prospectively.
- Iovance Biotherapeutics Announced Updated Results From Cohorts 1 And 2 Of Its Phase 2 IOV-LUN-202 Trial; 24.6% Objective Response Rate In 69 Patients With Non-Squamous mNSCLC, Consistent With Previously Reported ResultsThe company described the updated 24.6% ORR as consistent with earlier results, and the 17 responders included 15 confirmed responses and two unconfirmed partial responses.
About Iovance Biotherapeutics, Inc. Common Stock
Iovance Biotherapeutics is a commercial-stage biotech that makes tumor infiltrating lymphocyte (TIL) cell therapies for cancer. Its lead product, Amtagvi (lifileucel), was the first FDA-approved TIL therapy and is approved for advanced melanoma. Each dose is made from the patient's own tumor-derived immune cells and given at specialized treatment centers.
How it makes money
Iovance makes its money from product sales. Amtagvi brings in roughly 85% of revenue: about $102M of the roughly $122M total in Q3 2026. Proleukin (aldesleukin, an IL-2 drug given alongside Amtagvi and also sold on its own) brings in the rest. The company has guided to about $410–420M in total 2026 revenue, and gross margin recently reached about 60%. It has a network of 100+ authorized treatment centers in the US, Canada and Australia. It has been reporting losses, but they have been getting smaller.
What usually moves IOVA
- Amtagvi sales growth and the number of treatment centers
- Clinical trial results for new cancer types (e.g. lung cancer)
- Approvals in new countries and broader labels
- Manufacturing costs, gross margin and cash burn
- Leadership changes and updates to revenue guidance